Polypeptide variants with altered effector function
AssigneeGenentech, Inc.
InventorLeonard Presta
Life of this patent
Estimating the term…
Abstract
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
Claims7
An antibody comprising a variant human IgG1 Fc region which is not a native sequence Fc region, wherein the antibody comprises an amino acid substitution at amino acid position 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat, and wherein the variant Fc region binds human neonatal Fc receptor (FcRn) with increased binding affinity compared to a native sequence human IgG1 Fc region.
An antibody that binds vascular endothelial growth factor (VEGF) comprising a variant human IgG1 Fc region which is not a native sequence Fc region, wherein the antibody comprises an amino acid substitution at amino acid position 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat, and wherein the variant Fc region binds human neonatal Fc receptor (FcRn) with increased binding affinity compared to a native sequence human IgG1 Fc region.
An immunoadhesin comprising a variant human IgG1 Fc region which is not a native sequence Fc region, wherein the immunoadhesin comprises an amino acid substitution at amino acid position 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat, and wherein the variant Fc region binds human neonatal Fc receptor (FcRn) with increased binding affinity compared to a native sequence human IgG1 Fc region.
Dependencies are inferred from the claim text.